Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 February 2025 | Story Lacea Loader
University of the Free State Logo

On 12 February 2025, disruption of academic activities occurred on the Bloemfontein Campus of the University of the Free State (UFS); this followed the disruptions that occurred on 11 February 2025. On the Qwaqwa Campus, attempts to disrupt academic activities also occurred on 12 February 2024.

A memorandum of demands from the Institutional Student Representative Council (ISRC) was handed over to the university management on 11 February 2025, to which management responded; these demands are related to registration and funding. 

Financial concessions have been granted to students on two occasions so far this year to enable them to register. On 10 February 2025, the university granted follow-up concessions.

Furthermore, the institution’s Financial Working Group (FWG) – which includes representatives from the Institutional Student Representative Council (ISRC) – met regularly to determine how it could best assist students to register, taking into consideration the financial constraints of the university.

On the Bloemfontein Campus, 15 students were arrested on 12 February 2025 for transgression of the interdict; internal disciplinary processes are being instituted.

The university’s Protection Services has activated its protest management security escalation plan in accordance with the UFS Protest Management Policy; the situation on the campuses is being closely monitored.

All classes are continuing as normal, and no classes have been suspended. 

It is important to note the NSFAS-related progress made up until now: 

  • NSFAS funding has been confirmed and allocated to 25 551 students.
  • 22 246 of these students have already been successfully registered for the academic year.
  • NSFAS allowances were paid to 14 303 registered students on 3 February 2025.
  • On 17 February 2025, interim allowances will be paid to 7 943 students who were not registered at the time of the first round of payments.
Financial concessions have been granted to students during two occasions so far this year. On 10 February 2025, the university granted the following follow-up concessions: 

1. NSFAS-funded students

Criteria:

  • NSFAS funding for 2025 must be confirmed and reflected on the acknowledgement of debt (AOD) or registration verification document.
  • Historic debt may not exceed R35 000.

Concessions:

  • No payment is required.
  • Students will be eligible for full registration.

Criteria: 

  • NSFAS funding for 2025 must be confirmed and reflected on the acknowledgement of debt (AOD) or registration verification document.
  • Historic debt exceeding R35 000 but not exceeding R50 000.
      Concessions:
  • No payment is required.
  • Students will be eligible for provisional registration. Provisional registration applications must be submitted, and all other terms and conditions will apply.
2. Returning self-paying South African students:

Criteria:
  • Historic debt must not exceed R35 000.
  • Must sign an acknowledgment of debt (AOD).
Concessions:
  • No payment is required.
  • Students will be eligible for provisional registration. Provisional registration applications must be submitted, and all other terms and conditions will apply.
3. Final-year students:
  • Students with an average mark of above 60% were assisted with Monitoring bursaries.
  • 2025 final-year students with an average mark of between 50% and 60% will be assisted with the following concessions.  
Criteria:
  • Final-year students with a pass rate of between 50 and 60% and with outstanding fees up to a maximum of R60 000 to register provisionally.
Concessions:
  • No payment is required.
  • Students must complete a provisional registration application and attach an AOD, covering historic debt plus the first payment required for 2025 registration. 
4. Postgraduate students 
  • The Department of Finance is in contact with the Centre for Postgraduate Support to fast-track funding confirmations.
  • Postgraduate students who have studied at other institutions and wish to register at the UFS must contact Student Finance for possible assistance with registration.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept